Search results for "Epoetin beta"

showing 2 items of 2 documents

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

2007

Patients with cervical cancer frequently suffer from anemia. This two-stage, adaptive-design study investigated the effect of anemia correction with epoetin beta on treatment outcomes. Patients with stage IIB–IVA cervical cancer received radiochemotherapy (RCT) and were randomized to epoetin 150 IU/kg three times weekly (n = 34) or standard care (control; n = 40) for up to 12 weeks. Primary end point for stage 1 aimed to establish a correlation between anemia correction and treatment failure (no complete response or relapsing within 6 months after RCT initiation) as a proof of concept before moving into stage 2. Secondary end points included progression/relapse-free survival, overall surviv…

Adultmedicine.medical_specialtyAnemiaInjections Subcutaneousmedicine.medical_treatmentUterine Cervical NeoplasmsRisk AssessmentGastroenterologyDrug Administration Schedulelaw.inventionRandomized controlled trialReference ValueslawInternal medicinemedicineClinical endpointHumansAdverse effectErythropoietinSurvival analysisNeoplasm StagingProbabilityCervical cancerChemotherapyEpoetin betaDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyAnemiaMiddle Agedmedicine.diseaseCombined Modality TherapyImmunohistochemistrySurvival AnalysisRecombinant ProteinsSurgeryLogistic ModelsTreatment OutcomeOncologyChemotherapy AdjuvantFemaleRadiotherapy AdjuvantbusinessFollow-Up StudiesInternational Journal of Gynecologic Cancer
researchProduct

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

1998

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single …

MaleCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentUrologyAntineoplastic AgentsRadiation ToleranceCarboplatinRats Sprague-Dawleychemistry.chemical_compoundHemoglobinsInternal medicinemedicineAnimalsHumansRadiosensitivityErythropoietinEpoetin betaChemotherapybusiness.industryAnemiamedicine.diseaseCarboplatinRecombinant ProteinsRatsRadiation therapyEndocrinologyOncologychemistryErythropoietinToxicitySarcoma ExperimentalbusinessNeoplasm Transplantationmedicine.drugResearch ArticleBritish journal of cancer
researchProduct